Page last updated: 2024-11-13

fluorosalinosporamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fluorosalinosporamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24882226
CHEMBL ID514721
MeSH IDM0522861

Synonyms (3)

Synonym
CHEMBL514721
fluorosalinosporamide
(1r,4r,5s)-1-[(s)-[(1s)-cyclohex-2-en-1-yl]-hydroxymethyl]-4-(2-fluoroethyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID390500Inhibition of caspase-like activity of rabbit 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390499Inhibition of trypsin-like activity of rabbit 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390498Inhibition of chymotrypsin-like activity of rabbit 20S proteasome2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390497Stability in 20 mM HEPES buffer assessed as beta-lactone hydrolysis rate at pH 7.3 at 27 degC2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390507Inhibition of chymotrypsin-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 24 hrs after dialysis2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]